Want to become a CAPA member? Click here to sign on.

Biosimilars (also known as Subsequent Entry Biologics or SEBs)

CAPA is continuously updating this page on biosimilars (also called subsequent entry biologics or SEBs). We have recently updated our position paper and also created a video to help you understand this type of medication.

 

CAPA's Video on Biosimilars

We have created the video below to help explain the different types of medications you may take to manage your arthritis. We encourage you to ask your healthcare providers questions about your medications to help you best manage your arthritis.

CAPA's Position on Biosimilars

CAPA has produced a position on biosimilars as part of its Arthritis Month activities for 2016. See the English and French position papers below.

English                                                       French
     English SEB icon.jpg    French icon.jpg

CAPA believes biosimilars are another important treatment option for patients, and we've explained the major differences between small molecule, biologic, and biosimilar drugs, too. We have also created a presentation to accompany our position paper and explain a bit more about the different types of drugs (small molecule, biologic, generic, SEBs).

CAPA presentation on SEBs
SEB slide presentation - CAPA.png

The Biosimilar Focus Group Project Report, The Arthritis Society (TAS), Mar 2017

On March 28, 2017, The Arthritis Society (TAS) released the findings of a national, collaborative focus group project designed to examine the patient perspective on biologics and biosimilars for people who live with one of six inflammatory diseases: ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis.  This effort was led by TAS in collaboration with Canadian Arthritis Patient Alliance, Canadian Psoriasis Network, Crohn’s and Colitis Canada, and the Gastrointestinal Society. The findings highlighted the need for more patient education on biologics and biosimilars, as well as, treatment-decision support.

TAS_FocusGroupReport_Final_ENG_V5.pdf     

TAS_FocusGroupReport_FR_Final_v7.pdf

Biosimilars Focus Group Report - Press Release FINAL 03 28 2017.pdf     

Biosimilars Focus Group Report - Press Release FINAL 03 28 2017_FR.pdf

Here is a link to information on Health Canada's website about biosimilars. If you'd like to read more about terms and the regulations on biosimilars, click 

https://www.canada.ca/en/sr.html?st=s&s5bm3ts21rch=x&num=10&st1rt=1&langs=en&cdn=canada&hq=&_charset_=UTF-8&q=biosimilars+&wb-srch-sub=#wb-land

videos have been provided by Amgen.

IAPO Biosimilar Toolkit

CAPA is a member of IAPO (the International Association of Patient Organizations), and IAPO has developed a lot of very good, easy to understand information on biosimilars. Explore the IAPO Biosimilar Toolkit.

 

BIOTECanada Cross Disciplinary Meeting on SEBs

On June 5, 2014, BIOTECanada, the national biotechnology industry association, hosted a cross disciplinary meeting attended by specialist physicians (dermatology, gastroenterololgy, nephrology, oncology and rheumatology), patients, patient group representatives and pharmacists, who discussed their thoughts about SEBs. A member of CAPA attended this meeting and provided the arthritis patients' point of view. BIOTECanada produced a discussion paper that outlines key areas identified by the meeting's attendees about consideration of SEBs as a part of provincial/ territorial formularies.

^ Back to Top